Traders sold shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) on strength during trading on Friday. $10.80 million flowed into the stock on the tick-up and $30.59 million flowed out of the stock on the tick-down, for a money net flow of $19.79 million out of the stock. Of all equities tracked, Sage Therapeutics had the 15th highest net out-flow for the day. Sage Therapeutics traded up $2.27 for the day and closed at $97.71
SAGE has been the subject of a number of recent analyst reports. BMO Capital Markets reaffirmed a “buy” rating and set a $82.00 target price on shares of Sage Therapeutics in a report on Friday, July 28th. BidaskClub lowered Sage Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. HC Wainwright lifted their target price on Sage Therapeutics to $86.00 and gave the company a “neutral” rating in a report on Friday, August 4th. Needham & Company LLC set a $95.00 target price on Sage Therapeutics and gave the company a “buy” rating in a report on Friday, August 4th. Finally, Cowen Inc reaffirmed a “buy” rating and set a $100.00 target price on shares of Sage Therapeutics in a report on Friday, August 4th. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $105.71.
Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.98) by $0.01. The firm’s revenue was up .0% compared to the same quarter last year. equities research analysts forecast that Sage Therapeutics, Inc. will post -7.38 EPS for the current year.
Sage Therapeutics Company Profile
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.